Transforming Breast Cancer Together: Ευρωπαϊκή πρωτοβουλία για τον μεταστατικό καρκίνο του μαστού

Καθώς οι σύγχρονες θεραπευτικές παρεμβάσεις έχουν αυξήσει τον χρόνο επιβίωσης των ασθενών με μεταστατικό καρκίνο μαστού (σε κάποιους υποτύπους, όλο και περισσότερες ασθενείς μπορούν  να ζήσουν έως και 10 χρόνια με μεταστατικό/προχωρημένο καρκίνο μαστού), η TBCT θέλει να υπογραμμίσει πως οι ανάγκες των ασθενών αυτών θα πρέπει να λαμβάνονται περισσότερο υπόψη καθώς είναι ιδιαίτερες και συγκεκριμένες και ξεπερνούν το πλαίσιο της παρηγορητικής φροντίδας.

Ως εκ τούτου, ηγήθηκε της κοινής επιστολής, μέσα από την οποία καλεί τους υπεύθυνους χάραξης πολιτικών να διασφαλίσουν ότι η έκθεση της Ειδικής Επιτροπής του Ευρωπαϊκού Κοινοβουλίου για την Καταπολέμηση του Καρκίνου (BECA) και το Ευρωπαϊκό Σχέδιο Καταπολέμησης του Καρκίνου της Ευρωπαϊκής Επιτροπής θα αντικατοπτρίζουν την ιδιαίτερη προσοχή που αξίζει στον μεταστατικό ή προχωρημένο καρκίνο.

Μέσα από την κοινή επιστολή, οι υπογράφοντες καλούν την ΕΕ να διασφαλίσει ότι οι ανάγκες των ασθενών με μεταστατικό/προχωρημένο καρκίνο βρίσκονται στην πρώτη γραμμή του Ευρωπαϊκού Σχεδίου Καταπολέμησης του Καρκίνου και εκφράζουν το ενδιαφέρον τους να συνεργαστούν με την Ευρωπαϊκή Επιτροπή, το Κοινοβούλιο και τα κράτη μέλη για να διασφαλίσουν ότι τα κενά στη φροντίδα του μεταστατικού καρκίνου του μαστού αντιμετωπίζονται επαρκώς.

Ακολουθεί αναλυτικά η επιστολή της Transforming Breast Cancer Together στα αγγλικά:

Dear BECA Committee members,
Dear European Commission,

We, civil society, patient and professional organisations, industry and other stakeholders working in breast cancer welcome the European Commission’s ambitious Europe’s Beating Cancer Plan and the European Parliament’s Special Committee on Beating Cancer (BECA) efforts and commitment in delivering a comprehensive strategy to fight cancer.

Nevertheless, we as breast cancer stakeholders across different sectors would like to raise our deep
concern by the fact that the BECA report and suggested amendments do not reflect the special
attention that advanced/metastatic cancer deserves. This is especially concerning, in light of the
ongoing pandemic, that as we know has already caused severe disruption in screening and consequently increased late-stage diagnosis that is already presenting as a big challenge for the healthcare sector and will continue to be in the coming years. We were saddened to see that advanced/metastatic cancer is mentioned solely in the context of palliative care, when therapeutic innovations have increased the survival time of advanced/metastatic cancer patients. As a consequence and though advanced breast cancer remains mostly incurable, patients live on average between 3 and 5 years (in some subtypes, more and more patients can live up to 10 years with advanced/metastatic breast cancer) and have specific needs. As such, we urge the Committee to consider the specific needs of patients with latestage or metastatic cancer.

In light of the consideration of the BECA’s draft report, we as the breast-cancer community, urge
the BECA Committee as well as the European Commission’s DG SANTE Cancer Team to consider a
multitude of special needs of advanced and metastatic cancer patients:

Leveraging the European Commission’s European Health Data Space, TBCT believes that there
should be a harmonised breast cancer registry process in Europe for collecting breast cancer
data, including both early and metastatic breast cancer. Currently, most European cancer
registries do not collect data on relapse and therefore, we do not know how many Europeans
are living with metastatic cancer.

The quality of cancer care is of utmost importance. To achieve this, breast cancer patients
should be treated in accredited centres by a multidisciplinary and specialised team. In this
context, it is pivotal that Comprehensive Cancer Centres across the EU are equipped and ready
to address the specific needs of breast cancer patients including advanced and metastatic
breast cancer patients.

JOINT LETTER ON THE SPECIFIC
NEEDS OF PATIENTS WITH LATE
STAGE OR METASTATIC CANCER
JOINT LETTER ON THE SPECIFIC NEEDS OF PATIENTS
WITH LATE STAGE OR METASTATIC CANCER

We urge for more attention to be dedicated to improving the quality of life of patients and
their families, with a special attention for those with advanced/metastatic disease and terminal
conditions. Currently, no cure is known for advanced breast cancer, but therapeutic advances
allow patients with metastatic forms of cancer to live longer lives. Often, the disease affects
women in the prime of their lives when they have both career and childcare responsibilities.
Due to continuous treatment, these patients face severe long-term symptoms, such as fatigue,
cognitive and memory problems and peripheral neuropathy. Quality of life is thus the biggest
area of unmet need and access to care is very important to patients living with advanced
metastatic breast cancer.

Advanced communication skills should be an essential component of healthcare provider
education programs in different languages for all HCPs caring for patients with metastatic
cancer. We urge for policymakers to drive change in the common perception of advanced
cancer, from a “death sentence” to a condition with which patients can survive for a prolonged
period of time with a relative good quality of life and a productive life.

As the stigma and isolation has become a reality for most metastatic cancer patients, it is critical
to ensure that the general public is educated on the disease.

Lastly, it is pivotal to make sure that adequate support and help is provided to patients with
metastatic cancer patients to continue to work. This can be done by implementing legislation
that protects their right to work and guarantees flexible and accommodating workplace
environments that take into consideration the effects and the special needs of the patients.
The signatories of the letter (listed below) call on the EU to ensure that needs of metastatic/advanced cancer patients are at the forefront of Europe’s Beating Cancer Plan and express their interest to collaborate with the European Commission, the Parliament and Member States to ensure that the gaps in metastatic breast cancer care are adequately addressed.

Μπορείτε να δείτε την επιστολή και τους/τις υπογράφοντες/ουσες στον ακόλουθο σύνδεσμο: https://www.tbct.eu/wp-content/uploads/2021/12/TBCT_Metastatic-cancer-letter_december.pdf